References
- Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract 2008;62:1246-1254
- American Heart Association. Heart Disease and Stroke Statistics: 2007 Update. Dallas, TX. American Heart Association, 2007
- Coronary Heart Statistics 2008: United Kingdom. Available athttp://www.ws3.heartstats.web.baigent.net/datapage.asp?id=7998 [Accessed October 2009]
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383
- Bakhai A. The burden of coronary, cerebrovascular and peripheral arterial disease. Pharmacoecon 2004;22(Suppl 4):11-18
- Leys D. Atherothrombosis: a major health burden. Cerebrovasc Dis 2001;11(Suppl 2):1-4
- Mahoney EM, Wang K, Cohen DJ, et al. One-year costs in patients with a history of or at risk from atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 2008;1:38-45
- Steg PG, Bhatt DL, Wilson PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206
- Gandra SR, Lawrence LW, Parasuraman BM, et al. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Manag Care Pharm 2006;12:546-554
- Mody R, Kalsekar I, Kavookjian J, et al. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes. J Diabetes Complications 2007;21:75-83
- Blanchette CM, Gutierrez B, Ory C, et al. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm 2008;14:176-185
- Harley C, Li H, Corey-Lisle P, et al. Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. Soc Psychiatr Epidemiol 2007;42:690-697
- Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 2005;11:300-306
- Margolis J, Barron JJ, Grochulski D. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm 2005;11:727-734
- Kiechl S, Willeit J, for the Bruneck Study Group. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol 1999;19:1484-1490